EVO
Price
$3.48
Change
+$0.11 (+3.26%)
Updated
Sep 5 closing price
Capitalization
1.21B
59 days until earnings call
MKGAF
Price
$129.15
Change
+$1.90 (+1.49%)
Updated
Sep 5 closing price
Capitalization
55.52B
Interact to see
Advertisement

EVO vs MKGAF

Header iconEVO vs MKGAF Comparison
Open Charts EVO vs MKGAFBanner chart's image
Evotec SE
Price$3.48
Change+$0.11 (+3.26%)
Volume$85.94K
Capitalization1.21B
Merck KGaA
Price$129.15
Change+$1.90 (+1.49%)
Volume$594
Capitalization55.52B
EVO vs MKGAF Comparison Chart in %
Loading...
EVO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MKGAF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EVO vs. MKGAF commentary
Sep 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EVO is a Hold and MKGAF is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 07, 2025
Stock price -- (EVO: $3.48 vs. MKGAF: $129.15)
Brand notoriety: EVO and MKGAF are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: EVO: 131% vs. MKGAF: 111%
Market capitalization -- EVO: $1.21B vs. MKGAF: $55.52B
EVO [@Pharmaceuticals: Generic] is valued at $1.21B. MKGAF’s [@Pharmaceuticals: Generic] market capitalization is $55.52B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $67.95B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.93B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EVO’s FA Score shows that 1 FA rating(s) are green whileMKGAF’s FA Score has 1 green FA rating(s).

  • EVO’s FA Score: 1 green, 4 red.
  • MKGAF’s FA Score: 1 green, 4 red.
According to our system of comparison, EVO is a better buy in the long-term than MKGAF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EVO’s TA Score shows that 4 TA indicator(s) are bullish while MKGAF’s TA Score has 3 bullish TA indicator(s).

  • EVO’s TA Score: 4 bullish, 6 bearish.
  • MKGAF’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, MKGAF is a better buy in the short-term than EVO.

Price Growth

EVO (@Pharmaceuticals: Generic) experienced а -0.57% price change this week, while MKGAF (@Pharmaceuticals: Generic) price change was +4.36% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.10%. For the same industry, the average monthly price growth was +12.13%, and the average quarterly price growth was +87.01%.

Reported Earning Dates

EVO is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+0.10% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MKGAF($55.5B) has a higher market cap than EVO($1.21B). MKGAF YTD gains are higher at: -14.786 vs. EVO (-16.346). MKGAF has higher annual earnings (EBITDA): 5.87B vs. EVO (-121.33M). MKGAF has more cash in the bank: 1.57B vs. EVO (356M). EVO has less debt than MKGAF: EVO (107M) vs MKGAF (9.4B). MKGAF has higher revenues than EVO: MKGAF (21.2B) vs EVO (777M).
EVOMKGAFEVO / MKGAF
Capitalization1.21B55.5B2%
EBITDA-121.33M5.87B-2%
Gain YTD-16.346-14.786111%
P/E RatioN/A16.81-
Revenue777M21.2B4%
Total Cash356M1.57B23%
Total Debt107M9.4B1%
FUNDAMENTALS RATINGS
EVO vs MKGAF: Fundamental Ratings
EVO
MKGAF
OUTLOOK RATING
1..100
7064
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
23
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9570
PRICE GROWTH RATING
1..100
6378
P/E GROWTH RATING
1..100
292
SEASONALITY SCORE
1..100
7585

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MKGAF's Valuation (23) in the null industry is significantly better than the same rating for EVO (93). This means that MKGAF’s stock grew significantly faster than EVO’s over the last 12 months.

MKGAF's Profit vs Risk Rating (100) in the null industry is in the same range as EVO (100). This means that MKGAF’s stock grew similarly to EVO’s over the last 12 months.

MKGAF's SMR Rating (70) in the null industry is in the same range as EVO (95). This means that MKGAF’s stock grew similarly to EVO’s over the last 12 months.

EVO's Price Growth Rating (63) in the null industry is in the same range as MKGAF (78). This means that EVO’s stock grew similarly to MKGAF’s over the last 12 months.

EVO's P/E Growth Rating (2) in the null industry is significantly better than the same rating for MKGAF (92). This means that EVO’s stock grew significantly faster than MKGAF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EVOMKGAF
RSI
ODDS (%)
Bullish Trend 2 days ago
83%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
68%
Momentum
ODDS (%)
Bearish Trend 2 days ago
72%
Bearish Trend 2 days ago
67%
MACD
ODDS (%)
Bearish Trend 4 days ago
73%
Bullish Trend 2 days ago
65%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
74%
Bullish Trend 2 days ago
64%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
74%
Bullish Trend 2 days ago
62%
Advances
ODDS (%)
Bullish Trend about 1 month ago
69%
Bullish Trend 4 days ago
59%
Declines
ODDS (%)
Bearish Trend 5 days ago
80%
Bearish Trend 9 days ago
63%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
85%
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
67%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
EVO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MKGAF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PASSX58.880.57
+0.98%
T. Rowe Price Small-Cap Stock Adv
THCRX30.840.06
+0.19%
Thornburg Small/Mid Cap Growth R3
RYATX81.060.07
+0.09%
Rydex NASDAQ-100® A
DCUAX14.85N/A
N/A
DWS CROCI US A
HLFNX34.57-0.58
-1.65%
Hennessy Large Cap Financial Investor

MKGAF and

Correlation & Price change

A.I.dvisor indicates that over the last year, MKGAF has been loosely correlated with MKKGY. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if MKGAF jumps, then MKKGY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MKGAF
1D Price
Change %
MKGAF100%
+1.49%
MKKGY - MKGAF
49%
Loosely correlated
+1.66%
AQST - MKGAF
19%
Poorly correlated
+7.11%
INDV - MKGAF
17%
Poorly correlated
+1.01%
EVO - MKGAF
17%
Poorly correlated
+3.26%
EBS - MKGAF
16%
Poorly correlated
-0.66%
More